Assessment of Clinical Features in HIV-Infected Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in China
Table 4
GRACE score and medications at discharge and the one-year MACCE incidence.
PLWH (n = 48)
HIV-negative controls (n = 48)
value
GRACE score at discharge (mean and SD)
71.8 ± 24.8
69.5 ± 19.3
0.611
Medications at discharge (n, %)
DAPT
48 (100%)
47 (97.9%)
1.000
Statin
48 (100%)
48 (100%)
1.000
β receptor blocker
40 (83.3%)
41 (85.4%)
1.000
RAAS inhibitor
33 (68.8%)
38 (79.2%)
0.245
PLWH (n = 30)
HIV-negative controls (n = 37)
value
One-year MACCE (n, %)
6 (20%)
6 (12.5%)
0.688
Recurrent ACS (n, %)
3 (10%)
3 (8.1%)
1.000
Reintervention (n, %)
3 (10%)
1 (2.7%)
0.318
Stroke (n, %)
0 (0%)
2 (1.1%)
0.498
All-cause death (n, %)
0 (0%)
0 (0%)
1.000
MACCEs: major adverse cardiac and cerebrovascular events; PLWH: people living with HIV; DAPT: dual antiplatelet therapy; RAAS: renin angiotensin aldosterone system; ACS: acute coronary syndrome.
